Chengdu Kanghua Biological Products (300841) - Total Assets
Based on the latest financial reports, Chengdu Kanghua Biological Products (300841) holds total assets worth CN¥3.94 Billion CNY (≈ $576.18 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 300841 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Chengdu Kanghua Biological Products - Total Assets Trend (2015–2024)
This chart illustrates how Chengdu Kanghua Biological Products's total assets have evolved over time, based on quarterly financial data. See Chengdu Kanghua Biological Products (300841) shareholders funds for net asset value and shareholders' equity analysis.
Chengdu Kanghua Biological Products - Asset Composition Analysis
Current Asset Composition (December 2024)
Chengdu Kanghua Biological Products's total assets of CN¥3.94 Billion consist of 61.8% current assets and 38.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 24.9% |
| Accounts Receivable | CN¥1.30 Billion | 32.3% |
| Inventory | CN¥176.88 Million | 4.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥17.51 Million | 0.4% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Chengdu Kanghua Biological Products's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Chengdu Kanghua Biological Products (300841) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chengdu Kanghua Biological Products's current assets represent 61.8% of total assets in 2024, an increase from 51.4% in 2015.
- Cash Position: Cash and equivalents constituted 24.9% of total assets in 2024, up from 5.3% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 10.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 32.3% of total assets.
Chengdu Kanghua Biological Products Competitors by Total Assets
Key competitors of Chengdu Kanghua Biological Products based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
|
Clarity Pharmaceuticals Ltd
AU:CU6
|
Australia | AU$255.67 Million |
Chengdu Kanghua Biological Products - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.85 | 4.86 | 10.45 |
| Quick Ratio | 5.49 | 4.49 | 10.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.00 Billion | CN¥1.87 Billion | CN¥1.61 Billion |
Chengdu Kanghua Biological Products - Advanced Valuation Insights
This section examines the relationship between Chengdu Kanghua Biological Products's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.30 |
| Latest Market Cap to Assets Ratio | 0.22 |
| Asset Growth Rate (YoY) | -4.3% |
| Total Assets | CN¥4.03 Billion |
| Market Capitalization | $878.32 Million USD |
Valuation Analysis
Below Book Valuation: The market values Chengdu Kanghua Biological Products's assets below their book value (0.22x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Chengdu Kanghua Biological Products's assets decreased by 4.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Chengdu Kanghua Biological Products (2015–2024)
The table below shows the annual total assets of Chengdu Kanghua Biological Products from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.03 Billion ≈ $589.36 Million |
-4.32% |
| 2023-12-31 | CN¥4.21 Billion ≈ $615.95 Million |
+13.42% |
| 2022-12-31 | CN¥3.71 Billion ≈ $543.05 Million |
+22.96% |
| 2021-12-31 | CN¥3.02 Billion ≈ $441.63 Million |
+40.53% |
| 2020-12-31 | CN¥2.15 Billion ≈ $314.27 Million |
+211.65% |
| 2019-12-31 | CN¥689.14 Million ≈ $100.84 Million |
+41.78% |
| 2018-12-31 | CN¥486.07 Million ≈ $71.13 Million |
+76.92% |
| 2017-12-31 | CN¥274.74 Million ≈ $40.20 Million |
+36.68% |
| 2016-12-31 | CN¥201.01 Million ≈ $29.41 Million |
+18.42% |
| 2015-12-31 | CN¥169.74 Million ≈ $24.84 Million |
-- |
About Chengdu Kanghua Biological Products
Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines. In addition, it exports its products. Chengdu Kanghua Biological Produc… Read more